Oligosaccharyltransferase inhibition induces senescence in RTK-driven tumor cells

Nature Chemical Biology

Volumn 12, Issue 12, 2016, Pages 1023-1030

  Lopez Sambrooks, Cecilia ^a   Shrimal, Shiteshu ^b   Khodier, Carol ^c   Flaherty, Daniel P ^d   Rinis, Natalie ^a   Charest, Jonathan C ^a   Gao, Ningguo ^e   Zhao, Peng ^f   Wells, Lance ^f   Lewis, Timothy A ^c   Lehrman, Mark A ^e   Gilmore, Reid ^b   Golden, Jennifer E ^d,g   Contessa, Joseph N ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^d UNIVERSITY OF KANSAS   (United States)

^e UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^f UNIVERSITY OF GEORGIA   (United States)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OLIGOSACCHARYLTRANSFERASE; PROTEIN P21; PROTEIN TYROSINE KINASE; TRANSFERASE; UNCLASSIFIED DRUG; BENZAMIDE DERIVATIVE; CID2519269; DOLICHYL-DIPHOSPHOOLIGOSACCHARIDE - PROTEIN GLYCOTRANSFERASE; ENZYME INHIBITOR; GLYCOSYLTRANSFERASE; MEMBRANE PROTEIN; SULFONAMIDE;

ARTICLE; AUTOFLUORESCENCE; CELL CYCLE ARREST; CELL STRUCTURE; CONTROLLED STUDY; ENZYME INHIBITION; LUNG CANCER CELL LINE; PRIORITY JOURNAL; SENESCENCE; ANTAGONISTS AND INHIBITORS; CELL AGING; CELL CYCLE CHECKPOINT; CELL PROLIFERATION; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HIGH THROUGHPUT SCREENING; HUMAN; METABOLISM; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

BENZAMIDES; CELL AGING; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; HEXOSYLTRANSFERASES; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; MEMBRANE PROTEINS; MOLECULAR STRUCTURE; RECEPTOR PROTEIN-TYROSINE KINASES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES;

EID: 84989918361     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2194     Document Type: Article

References (45)

1. Zielinska, D.F., Gnad, F., Wi?niewski, J.R., Mann, M. Precision mapping of an in vivo N-glycoproteome reveals rigid topological and sequence constraints. Cell 141, 897-907 (2010).
2. Freeze, H.H. Genetic defects in the human glycome. Nat. Rev. Genet. 7, 537-551 (2006).
3. Lehrman, M.A. Teaching dolichol-linked oligosaccharides more tricks with alternatives to metabolic radiolabeling. Glycobiology 17, 75R-85R (2007).
4. Takatsuki, A., Arima, K., Tamura, G. Tunicamycin, a new antibiotic. I. Isolation and characterization of tunicamycin. J. Antibiot. (Tokyo) 24, 215-223 (1971).
5. Helenius, J., et al. Translocation of lipid-linked oligosaccharides across the ER membrane requires Rft1 protein. Nature 415, 447-450 (2002).
6. Frank, C.G., Sanyal, S., Rush, J.S., Waechter, C.J., Menon, A.K. Does Rft1 flip an N-glycan lipid precursor? Nature 454, E3-E4 (2008).
7. Jelk, J., et al. Glycoprotein biosynthesis in a eukaryote lacking the membrane protein Rft1. J. Biol. Chem. 288, 20616-20623 (2013).
8. Aebi, M. N-linked protein glycosylation in the ER. Biochim. Biophys. Acta 1833, 2430-2437 (2013).
9. Kelleher, D.J., Gilmore, R. An evolving view of the eukaryotic oligosaccharyltransferase. Glycobiology 16, 47R-62R (2006).
10. Pfeffer, S., et al. Structure of the mammalian oligosaccharyl-transferase complex in the native ER protein translocon. Nat. Commun. 5, 3072 (2014).
11. Reiss, G., te Heesen, S., Gilmore, R., Zufferey, R., Aebi, M. A specific screen for oligosaccharyltransferase mutations identifies the 9 kDa OST5 protein required for optimal activity in vivo and in vitro. EMBO J. 16, 1164-1172 (1997).
12. Zufferey, R., et al. STT3, a highly conserved protein required for yeast oligosaccharyl transferase activity in vivo. EMBO J. 14, 4949-4960 (1995).
13. Schwarz, F., Aebi, M. Mechanisms and principles of N-linked protein glycosylation. Curr. Opin. Struct. Biol. 21, 576-582 (2011).
14. Ruiz-Canada, C., Kelleher, D.J., Gilmore, R. Cotranslational and posttranslational N-glycosylation of polypeptides by distinct mammalian OST isoforms. Cell 136, 272-283 (2009).
15. Shrimal, S., Gilmore, R. Glycosylation of closely spaced acceptor sites in human glycoproteins. J. Cell Sci. 126, 5513-5523 (2013).
16. Cherepanova, N.A., Shrimal, S., Gilmore, R. Oxidoreductase activity is necessary for N-glycosylation of cysteine-proximal acceptor sites in glycoproteins. J. Cell Biol. 206, 525-539 (2014).
17. Roboti, P., High, S. The oligosaccharyltransferase subunits OST48, DAD1 and KCP2 function as ubiquitous and selective modulators of mammalian N-glycosylation. J. Cell Sci. 125, 3474-3484 (2012).
18. Blomen, V.A., et al. Gene essentiality and synthetic lethality in haploid human cells. Science 350, 1092-1096 (2015).
19. Freeze, H.H., Aebi, M. Altered glycan structures: The molecular basis of congenital disorders of glycosylation. Curr. Opin. Struct. Biol. 15, 490-498 (2005).
20. Contessa, J.N., et al. Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel target for cancer therapy. Clin. Cancer Res. 16, 3205-3214 (2010).
21. Dennis, J.W., Nabi, I.R., Demetriou, M. Metabolism, cell surface organization, disease. Cell 139, 1229-1241 (2009).
22. Croci, D.O., et al. Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156, 744-758 (2014).
23. Weinstein, I.B., Joe, A. Oncogene addiction. Cancer Res. 68, 3077-3080, discussion 3080 (2008).
24. Kellenberger, C., Hendrickson, T.L., Imperiali, B. Structural and functional analysis of peptidyl oligosaccharyl transferase inhibitors. Biochemistry 36, 12554-12559 (1997).
25. Weerapana, E., Imperiali, B. Peptides to peptidomimetics: Towards the design and synthesis of bioavailable inhibitors of oligosaccharyl transferase. Org. Biomol. Chem. 1, 93-99 (2003).
26. Bennett, D.C., et al. High-throughput screening identifies aclacinomycin as a radiosensitizer of EGFR-mutant non-small cell lung cancer. Transl. Oncol. 6, 382-391 (2013).
27. Baell, J.B., Holloway, G.A. New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays. J. Med. Chem. 53, 2719-2740 (2010).
28. Auld, D.S., et al. Molecular basis for the high-affinity binding and stabilization of firefly luciferase by PTC124. Proc. Natl. Acad. Sci. USA 107, 4878-4883 (2010).
29. Maeda, Y., Tomita, S., Watanabe, R., Ohishi, K., Kinoshita, T. DPM2 regulates biosynthesis of dolichol phosphate-mannose in mammalian cells: Correct subcellular localization and stabilization of DPM1, binding of dolichol phosphate. EMBO J. 17, 4920-4929 (1998).
30. Anand, M., et al. Requirement of the Lec35 gene for all known classes of monosaccharide-P-dolichol-dependent glycosyltransferase reactions in mammals. Mol. Biol. Cell 12, 487-501 (2001).
31. Mohorko, E., et al. Structural basis of substrate specificity of human oligosaccharyl transferase subunit N33/Tusc3 and its role in regulating protein N-glycosylation. Structure 22, 590-601 (2014).
32. Kelleher, D.J., Karaoglu, D., Gilmore, R. Large-scale isolation of dolichol-linked oligosaccharides with homogeneous oligosaccharide structures: Determination of steady-state dolichol-linked oligosaccharide compositions. Glycobiology 11, 321-333 (2001).
33. Shrimal, S., Trueman, S.F., Gilmore, R. Extreme C-terminal sites are posttranslocationally glycosylated by the STT3B isoform of the OST. J. Cell Biol. 201, 81-95 (2013).
34. Jafari, R., et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat. Protoc. 9, 2100-2122 (2014).
35. Paez, J.G., et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
36. Pao, W., et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. USA 101, 13306-13311 (2004).
37. Sordella, R., Bell, D.W., Haber, D.A., Settleman, J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (2004).
38. Weiss, J., et al. Frequent and focal FGFR1 amplification associates with therapeutically tractable FGFR1 dependency in squamous cell lung cancer. Sci. Transl. Med. 2, 62ra93 (2010).
39. Schneider, A., et al. Successful prenatal mannose treatment for congenital disorder of glycosylation-Ia in mice. Nat. Med. 18, 71-73 (2011).
40. Leung, E.L., et al. SRC promotes survival and invasion of lung cancers with epidermal growth factor receptor abnormalities and is a potential candidate for molecular-targeted therapy. Mol. Cancer Res. 7, 923-932 (2009).
41. Shimamura, T., Lowell, A.M., Engelman, J.A., Shapiro, G.I. Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins. Cancer Res. 65, 6401-6408 (2005).
42. Kobayashi, S., et al. Transcriptional profiling identifies cyclin D1 as a critical downstream effector of mutant epidermal growth factor receptor signaling. Cancer Res. 66, 11389-11398 (2006).
43. Arrowsmith, C.H., et al. The promise and peril of chemical probes. Nat. Chem. Biol. 11, 536-541 (2015).
44. Gao, N., Lehrman, M.A. Analyses of dolichol pyrophosphate-linked oligosaccharides in cell cultures and tissues by fluorophore-assisted carbohydrate electrophoresis. Glycobiology 12, 353-360 (2002).
45. Gao, N., Shang, J., Lehrman, M.A. Analysis of glycosylation in CDG-Ia fibroblasts by fluorophore-assisted carbohydrate electrophoresis: Implications for extracellular glucose and intracellular mannose 6-phosphate. J. Biol. Chem. 280, 17901-17909 (2005).